This retrospective, observational study is aimed at analyzing real‐world data (RWD) from a digital device (ESYSTA, Emperra GmbH E‐Health Technologies, Germany) that incorporates both CGM and BGM data to enhance the glycemic control and self‐management of insulin‐treated people with diabetes. The gene discussed is INS; the disease is diabetes mellitus.